An easy-to-use app provides life-saving tips, tools, and resources for outdoor enthusiasts and first responders.
BTG Specialty Pharmaceuticals 24 June 2020
Summer’s here, and with COVID-19 still surging in the US, more and more people are looking to get outside – and away from crowds.
Venturing off the beaten path may be one reason why emergency medical authorities are reporting higher number of snake bites than average: near Los Angeles and in the Bay Area, in Peoria and Phoenix, and in North Carolina, Texas, and Nevada.
No matter how prepared you may be – and we’ve outlined some general safety tips below – the panic and fear that arises in the moment of a snake bite can often send thoughts running. Fortunately, like everything else nowadays, there’s an easy-to-use app that can provide life-saving tips, tools, and resources for outdoor enthusiasts and the first responders who, in case of an emergency, will treat them.
Here’s a sneak peek into the educational offerings of the SnakeBite911 app.
Snakes do not intend to attack people or large animals; most snake bites occur if the snake feels threatened and therefore attempts to defend itself. So, if you’re heading outside…
This does not constitute medical advice and does not replace a consultation with your doctor or emergency medicine clinician.
Call 911 immediately.
Delays in treatment can lead to further cellular damage, therefore get the bite victim to the Emergency Room, as quickly as possible!
Remove their jewelry and any tight-fitting clothes, including shoes.
Take a new photo every 15 minutes until you get to the Emergency Room, capturing the bite zone and any red swollen areas. This will help the doctor's diagnosis on arrival at the Emergency Room.
Keep the bitten limb raised to the level of the heart (e.g. drape the arm over the chest).
Any unnecessary increase in heart rate can increase the rate at which the venom spreads.
CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.
IMPORTANT SAFETY INFORMATION
Do not administer CroFab® to patients with a known history of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.
WARNINGS AND PRECAUTIONS
Coagulopathy: In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.
Hypersensitivity Reactions: Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).
The most common adverse reactions (incidence ≥ 5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.